Abdu Nuru, Idrisnur Saleh, Said Hanae, Kifle Lude, Habte Natnael, Ghirmai Semira, Tewelde Tomas, Siele Senai Mihreteab, Tesfamariam Eyasu H
Medicine Information Services Unit, Pharmacy Services Division, Department of Medical Services, Ministry of Health, Asmara, Eritrea.
Product Evaluation and Registration Unit, National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea.
BMC Geriatr. 2025 Feb 3;25(1):76. doi: 10.1186/s12877-025-05736-9.
Older adults often face several chronic illnesses that require them to take multiple medications. The increased number of prescribed medications has led to more complex medication regimens, putting older adults at a higher risk of potential drug-drug interactions, inappropriate medication prescribing, and adverse events. This study aimed to assess inappropriate prescribing practices, polypharmacy, medication regimen complexity, and their determinants in older adults.
A cross-sectional study was conducted among older adults (aged 65 years and above) who visited three referral hospitals in Asmara, Eritrea, between June and August, 2023. A stratified random sampling technique was used, and data were collected from patient prescriptions, medical cards, and through interviews with a questionnaire. Inappropriate medication prescribing was evaluated using STOPP (Screening Tool of Older Person's Prescriptions)/ START (Screening Tool to Alert to Right Treatment) criteria version 3. Potential drug-drug interactions (pDDIs) and medication regimen complexity (MRC) were assessed using Lexi-comp drug interaction checker and MRC index, respectively. Descriptive statistics, logistic regression, Pearson's correlation coefficient, independent samples t-test, one-way Analysis of Variance, and paired t-test were employed using IBM SPSS (version-26.0).
A total of 430 respondents, with a similar male to female ratio, were included. The prevalence of polypharmacy was 5.3% (95%CI: 3.2, 7.5). Moreover, the prevalence of clinically significant pDDI was 51% (95%CI: 46, 56). The most common medicines involved in clinically significant pDDIs were enalapril (n = 179) and acetylsalicylic acid (n = 124). The presence of chronic illness (AOR = 7.58, 95%CI: 3.73, 15.39) and the number of drugs prescribed (AOR = 2.80, 95%CI: 1.91, 4.10) were predictors of clinically significant pDDIs. The prevalence of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) were 27.4% (95% CI: 23.4, 31.8) and 13.3% (95% CI: 10.3, 16.7), respectively. The most common PIMs were long-acting sulfonylureas (n = 63) and aldosterone antagonists (n = 19). Besides, proton pump inhibitors (PPIs) (n = 41) and cardio-selective beta-blockers (n = 14) were the most common PPOs identified. Age (AOR: 0.95, 95% CI: 0.92, 0.98), presence of chronic illness (AOR: 1.51, 95% CI: 0.81, 2.80), and number of drugs prescribed (AOR: 2.01, 95% CI: 1.51, 2.69) were significant factors associated with PIM. MRCI score was a significant determinant of PPO (AOR: 1.25, 95% CI: 1.14, 1.38). The mean (SD) of the overall MRCI score was 9.1 (3.7), with dose frequency being the major contributor. The number of drugs prescribed was a determinant of MRCI score (r = 0.625, p < 0.001).
Inappropriate medication prescribing and clinically significant drug-drug interactions were common among older adults, highlighting the need for immediate attention from policymakers, program managers, and healthcare professionals.
老年人常常面临多种慢性疾病,需要服用多种药物。处方药物数量的增加导致药物治疗方案更加复杂,使老年人面临潜在药物相互作用、不适当药物处方和不良事件的更高风险。本研究旨在评估老年人中不适当的处方行为、多重用药、药物治疗方案复杂性及其决定因素。
于2023年6月至8月在厄立特里亚阿斯马拉的三家转诊医院对老年人(65岁及以上)进行了一项横断面研究。采用分层随机抽样技术,通过患者处方、医疗卡以及问卷调查收集数据。使用STOPP(老年人处方筛查工具)/START(正确治疗警报筛查工具)第3版标准评估不适当的药物处方。分别使用Lexi-comp药物相互作用检查器和MRC指数评估潜在药物相互作用(pDDIs)和药物治疗方案复杂性(MRC)。使用IBM SPSS(版本26.0)进行描述性统计、逻辑回归、皮尔逊相关系数、独立样本t检验、单因素方差分析和配对t检验。
共纳入430名受访者,男女比例相似。多重用药的患病率为5.3%(95%CI:3.2,7.5)。此外,具有临床意义的pDDI的患病率为51%(95%CI:46,56)。参与具有临床意义的pDDIs的最常见药物是依那普利(n = 179)和乙酰水杨酸(n = 124)。慢性病的存在(AOR = 7.58,95%CI:3.73,15.39)和处方药物数量(AOR = 2.80,95%CI:1.91,4.10)是具有临床意义的pDDIs的预测因素。潜在不适当药物(PIMs)和潜在处方遗漏(PPOs)的患病率分别为27.4%(95%CI:23.4,31.8)和13.3%(95%CI:10.3,16.7)。最常见的PIMs是长效磺脲类药物(n = 63)和醛固酮拮抗剂(n = 19)。此外,质子泵抑制剂(PPIs)(n = 41)和心脏选择性β受体阻滞剂(n = 14)是确定的最常见的PPOs。年龄(AOR:0.95,95%CI:0.92,0.98)、慢性病的存在(AOR:1.51,95%CI:0.81,2.80)和处方药物数量(AOR:2.01,95%CI:1.51,2.69)是与PIM相关的显著因素。MRCI评分是PPO的显著决定因素(AOR:1.25,95%CI:1.14,1.38)。总体MRCI评分的平均值(SD)为9.1(3.7),剂量频率是主要贡献因素。处方药物数量是MRCI评分的决定因素(r = 0.625,p < 0.001)。
老年人中不适当的药物处方和具有临床意义的药物相互作用很常见,这突出表明政策制定者、项目管理者和医疗保健专业人员需要立即予以关注。